March 29, 2017 / 11:10 AM / 8 months ago

BRIEF-Revive Therapeutics provides corporate update

March 29 (Reuters) - Revive Therapeutics Ltd

* Revive Therapeutics provides corporate update

* Says has engaged with five clinical sites to advance phase 2 study of revenue-004 (bucillamine) in cystinuria Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below